Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
89 hedge funds and large institutions have $382M invested in Inozyme Pharma in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 33 reducing their positions, and 9 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
79% more capital invested
Capital invested by funds: $214M → $382M (+$168M)
11% more funds holding
Funds holding: 80 → 89 (+9)
0.52% less ownership
Funds ownership: 81.27% → 80.74% (-0.52%)
33% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 33
82% less call options, than puts
Call options by funds: $45K | Put options by funds: $246K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
+$4.15M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.23M |
| 3 |
EAM
Exome Asset Management
New York
|
+$1.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.34M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$824K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
-$2.52M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$1.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.67M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.38M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.14M |
INZY Hedge Fund Activity: Q1 2024 in Review
89 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2024, worth a combined $382M — up 79% from $214M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new INZY positions and 9 closed out — a net gain of 9 holders — while 22 added to existing stakes and 33 trimmed.
The largest buyer was Affinity Asset Advisors, adding an estimated $4.15M. The largest seller was Samlyn Capital, cutting an estimated $2.52M.
- 89 institutional investors held Inozyme Pharma (INZY) as of Q1 2024, up from 80 in Q4 2023.
- Funds reported $382M of Inozyme Pharma stock for Q1 2024, up 79% quarter-over-quarter.
- 18 funds opened new Inozyme Pharma positions in Q1 2024 and 9 closed out, a net change of +9 holders.
- The largest Inozyme Pharma buyer in Q1 2024 was Affinity Asset Advisors, an estimated $4.15M added.
- The largest Inozyme Pharma seller in Q1 2024 was Samlyn Capital, an estimated $2.52M sold.
Based on aggregated 13F filings for Q1 2024.